Gut & Inflammation Repair

Archival Status

The Gut and Inflammation Repair protocol pairs BPC-157 and KPV (a tripeptide fragment of alpha-MSH) to address intestinal barrier integrity and systemic inflammation through complementary mechanisms targeting both the structural components of the gut lining and the inflammatory signaling pathways that drive mucosal damage. BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide derived from a gastric juice protein sequence. Its gut-specific research profile is extensive: studies in rodent models of inflammatory bowel disease, Crohn's disease, ulcerative colitis, and anastomotic healing have demonstrated acceleration of mucosal repair, reduction of ulcer area, restoration of goblet cell density, and normalization of tight junction protein expression (ZO-1, claudin, occludin). BPC-157 also modulates the enteric nervous system through NO pathway activation and upregulation of the cytoprotective prostaglandin E2 system. Its systemic anti-inflammatory effects extend beyond the gut, with research demonstrating reduction of hepatic and systemic inflammatory markers in animal models. KPV (Lys-Pro-Val) is a tripeptide comprising the C-terminal active core of alpha-melanocyte stimulating hormone (alpha-MSH). Unlike the full alpha-MSH peptide, KPV is small enough to be absorbed orally and crosses the intestinal epithelium intact, allowing it to act directly on subepithelial immune cells. Its primary mechanism is binding to MC1R (melanocortin-1 receptor) and MC3R on macrophages, dendritic cells, and T cells in the lamina propria, suppressing NF-kB activation and the downstream production of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6, IL-17). Rodent studies of DSS-induced colitis and Crohn's disease models show significant improvement in disease activity index, histological damage scores, and cytokine profiles with KPV treatment. The mechanistic synergy is complementary: BPC-157 repairs the physical gut barrier and promotes mucosal healing, while KPV modulates the immune and inflammatory response within the lamina propria. Together, they address both the structural defect and the inflammatory driver that sustains it. Research applications include inflammatory bowel disease, leaky gut syndrome research, post-antibiotic gut dysbiosis, and systemic inflammatory conditions with gut-axis components.